{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:24:01Z","timestamp":1792567441236,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,9,2]],"date-time":"2008-09-02T00:00:00Z","timestamp":1220313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00296-008-0689-2","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T08:19:30Z","timestamp":1220257170000},"page":"311-315","source":"Crossref","is-referenced-by-count":84,"title":["Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study"],"prefix":"10.1007","volume":"29","author":[{"given":"Johann D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvis","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,2]]},"reference":[{"key":"689_CR1","volume-title":"Treatment of metabolic bone disease. Management strategy and drug therapy","author":"JD Ringe","year":"2000","unstructured":"Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London"},{"key":"689_CR2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jmhg.2006.11.003","volume":"4","author":"JD Ringe","year":"2007","unstructured":"Ringe JD (2007) Treatment of osteoporosis in men. J Mens Health Gend (Elsevier) 4:326\u2013333","journal-title":"J Mens Health Gend (Elsevier)"},{"key":"689_CR3","doi-asserted-by":"crossref","unstructured":"Seeman E (2004) Invest in your bones. Osteoporosis in men: the \u2018silent epidemic\u2019 strikes men too. International Osteoporosis Foundation, Available at http:\/\/www.iofbonehealth.org\/download\/osteofound\/filemanager\/publications\/pdf\/osteoporosis_in_men.pdf","DOI":"10.1007\/978-0-85729-402-9_20"},{"key":"689_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/ard.59.10.765","volume":"59","author":"JM Kaufman","year":"2000","unstructured":"Kaufman JM, Johnell O, Abadie E et al (2000) Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59:765\u2013772. doi: 10.1136\/ard.59.10.765","journal-title":"Ann Rheum Dis"},{"key":"689_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/ard.2004.034611","volume":"65","author":"I Pande","year":"2006","unstructured":"Pande I, Scott DL, O\u2019Neill TW, Pritchard C, Woolf AD, Davis MJ (2006) Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65:87\u201392. doi: 10.1136\/ard.2004.034611","journal-title":"Ann Rheum Dis"},{"key":"689_CR6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342. doi: 10.1007\/s00198-003-1490-4","journal-title":"Osteoporos Int"},{"key":"689_CR7","doi-asserted-by":"crossref","unstructured":"Gajic-Veljanoski O, Sebaldt RJ, Davis AM et al. (2007) Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis. Osteoporos Int (Epub ahead of print)","DOI":"10.1007\/s00198-007-0340-1"},{"key":"689_CR8","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/archinte.163.18.2165","volume":"163","author":"A Feldstein","year":"2003","unstructured":"Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. A gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165\u20132172. doi: 10.1001\/archinte.163.18.2165","journal-title":"Arch Intern Med"},{"key":"689_CR9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00198-005-1950-0","volume":"16","author":"AC Feldstein","year":"2005","unstructured":"Feldstein AC, Nichols G, Orwoll E et al (2005) The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 16:953\u2013962. doi: 10.1007\/s00198-005-1950-0","journal-title":"Osteoporos Int"},{"key":"689_CR10","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","volume":"86","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252\u20135255. doi: 10.1210\/jc.86.11.5252","journal-title":"J Clin Endocrinol Metab"},{"key":"689_CR11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610. doi: 10.1056\/NEJM200008313430902","journal-title":"N Engl J Med"},{"key":"689_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","volume":"26","author":"JD Ringe","year":"2006","unstructured":"Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427\u2013431. doi: 10.1007\/s00296-005-0004-4","journal-title":"Rheumatol Int"},{"key":"689_CR13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMcp0707217","volume":"358","author":"PR Ebeling","year":"2008","unstructured":"Ebeling PR (2008) Osteoporosis in men. N Engl J Med 358:1474\u20131482. doi: 10.1056\/NEJMcp0707217","journal-title":"N Engl J Med"},{"key":"689_CR14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00002512-200522090-00003","volume":"22","author":"HK Kamel","year":"2005","unstructured":"Kamel HK (2005) Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 22:741\u2013748. doi: 10.2165\/00002512-200522090-00003","journal-title":"Drugs Aging"},{"key":"689_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s001980200013","volume":"13","author":"JD Ringe","year":"2002","unstructured":"Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: Recent advances with alendronate. Osteoporos Int 13:195\u2013199. doi: 10.1007\/s001980200013","journal-title":"Osteoporos Int"},{"key":"689_CR16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510\u2013516. doi: 10.1007\/s00198-004-1713-3","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"689_CR17","first-page":"S110","volume":"21","author":"S Boonen","year":"2006","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2006) Risedronate Is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. JBMR 21(Suppl 1):S110. doi: 10.1359\/jbmr.06s221","journal-title":"JBMR"},{"key":"689_CR18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1532-5415.2002.50163.x","volume":"50","author":"M Fransen","year":"2002","unstructured":"Fransen M, Woodward M, Norton R, Robinson E, Butler M, Campbell AJ (2002) Excess mortality or institutionalization after hip fracture: men are at greater risk than women. J Am Geriatr Soc 50:685\u2013690. doi: 10.1046\/j.1532-5415.2002.50163.x","journal-title":"J Am Geriatr Soc"},{"key":"689_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229\u2013238. doi: 10.1007\/s00198-004-1811-2","journal-title":"Osteoporos Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-008-0689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-008-0689-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-008-0689-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:16:12Z","timestamp":1559027772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-008-0689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s00296-008-0689-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,2]]}}}